Noradrenaline Hameln (Noradrenaline Tartrate)

Norepinephrine (noradrenaline) binds directly to alpha‑1 and beta‑1 adrenergic receptors. Alpha‑1 activation causes peripheral blood‑vessel constriction, increasing systemic vascular resistance, while beta‑1 activation boosts heart‑muscle contractility and rate, together elevating cardiac output and arterial pressure.

The dosing regimen for Noradrenaline Hameln is determined by the prescribing clinician based on the patient’s hemodynamic status, response to therapy, and institutional protocols. The prescriber sets the infusion rate and titrates it to achieve target blood‑pressure goals.

Safety data for Noradrenaline Hameln in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and required import documentation.

Noradrenaline Hameln is a first‑line vasopressor with strong alpha‑1 activity and moderate beta‑1 effects, offering reliable blood‑pressure support with less tachycardia than pure beta‑agonists. Compared with dopamine, it provides more predictable vasoconstriction and fewer arrhythmic risks, making it preferred in many septic‑shock protocols.

The product must be stored at 2‑8 °C, protected from light, and should never be frozen or shaken. Keep the vial in its original packaging until use and discard any solution that appears discolored or contains particles.

Noradrenaline Hameln is given by intravenous infusion, typically through a central venous catheter. The infusion is started at a low rate and titrated according to blood‑pressure response, with continuous hemodynamic monitoring throughout the treatment.

Serious risks include myocardial ischemia, severe hypertension, tissue necrosis from extravasation, and reflex bradycardia. Immediate attention is required if chest pain, sudden blood‑pressure spikes, or signs of local tissue injury occur during infusion.

Patients with known hypersensitivity to norepinephrine or any component of the formulation should not receive the drug. Caution is also advised in individuals with severe peripheral vascular disease, uncontrolled hypertension, or recent myocardial infarction, where alternative therapies may be preferred.